Tirzepatide Titration (24 weeks)
FDA Zepbound label titration: 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, escalating every 4 weeks to the 15mg maintenance dose.
Concentration over time
| Date | Tirzepatide (Mounjaro) |
|---|---|
| W1 | 0.00 |
| W3 | 1972.30 |
| W5 | 2240.37 |
| W7 | 4249.11 |
| W9 | 4522.13 |
| W11 | 6531.36 |
| W13 | 6804.39 |
| W15 | 8813.61 |
| W17 | 9086.64 |
| W19 | 11096.41 |
| W21 | 11369.44 |
| W23 | 13378.85 |
| W25 | 13651.87 |
Protocol summary
Tirzepatide Titration (24 weeks) · 24 weeks starting Jul 20, 26
- Tirzepatide (Mounjaro) — 2.50 mg Every 7 days, weeks 0–3
- Tirzepatide (Mounjaro) — 5.00 mg Every 7 days, weeks 4–7
- Tirzepatide (Mounjaro) — 7.50 mg Every 7 days, weeks 8–11
- Tirzepatide (Mounjaro) — 10.0 mg Every 7 days, weeks 12–15
- Tirzepatide (Mounjaro) — 12.5 mg Every 7 days, weeks 16–19
- Tirzepatide (Mounjaro) — 15.0 mg Every 7 days, weeks 20–24
Protocol overview
- Category
- weightloss
- Duration
- 24 weeks
- Compounds
- 6
- Tags
- glp-1, gip, weightloss, tirzepatide, titration
Compounds in this protocol
- Tirzepatide 2.5mg — 2.5 mg, every-7-days (weeks 0-3)
- Tirzepatide 5mg — 5 mg, every-7-days (weeks 4-7)
- Tirzepatide 7.5mg — 7.5 mg, every-7-days (weeks 8-11)
- Tirzepatide 10mg — 10 mg, every-7-days (weeks 12-15)
- Tirzepatide 12.5mg — 12.5 mg, every-7-days (weeks 16-19)
- Tirzepatide 15mg — 15 mg, every-7-days (weeks 20-24)
How to read this protocol
The chart above shows the modeled blood concentration of each compound over the 24-week duration. Each compound accumulates toward steady state (roughly 5 half-lives). The peak-to-trough ratio within each dose interval depends on the injection frequency relative to the half-life.
Use the [peak-trough estimator](/tools/peak-trough) to see predicted levels at any point, or the [clearance calculator](/tools/clearance) to estimate washout after the protocol ends. The [PCT planner](/pct-planner) estimates when to start post-cycle therapy.
Educational only. Not medical advice. Concentration values are modeled estimates based on population pharmacokinetics, not predictions of individual blood levels.